SCHEMBL19791186

SCHEMBL19791186

C[C@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 7/20 0.55
▸ GHSR Q92847 1/20 0.51
▸ IL23R Q5VWK5 2/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.49
▸ PRMT1 Q99873 1/20 0.49
▸ ERAP2 Q6P179 1/20 0.49
▸ ACE P12821 1/20 0.49
▸ NPBWR1 P48145 1/20 0.48
▸ PTH1R Q03431 1/20 0.48
▸ MAGI3 Q5TCQ9 1/20 0.48
▸ GLP1R P43220 1/20 0.48
▸ GCGR P47871 1/20 0.48
▸ GIPR P48546 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19791177 1.00 KISS1R (0.55) KISS1RGHSRIL23RRXFP1PRMT1
SCHEMBL19791252 0.95 KISS1R (0.55) KISS1RIL23RRXFP1PRMT1NPBWR1
SCHEMBL19791161 0.94 IL23R (0.56) KISS1RIL23RRXFP1ACEMAGI3
SCHEMBL19791170 0.94 IL23R (0.56) KISS1RIL23RRXFP1PRMT1MAGI3
SCHEMBL29493330 0.89 GHSR (0.60) KISS1RGHSRIL23R
SCHEMBL31345040 0.89 KISS1R (0.56) KISS1RPRMT1ERAP2ACENPBWR1
SCHEMBL19791175 0.88 IL23R (0.51) KISS1RIL23RRXFP1NPBWR1MAGI3
SCHEMBL19791189 0.88 KISS1R (0.52) KISS1RIL23RPRMT1ERAP2ACE
SCHEMBL31232961 0.88 IL23R (0.51) KISS1RIL23RACENPBWR1
SCHEMBL29608623 0.87 KISS1R (0.53) KISS1RGHSRPRMT1ACENPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148474-A1 PEPTIDE DERIVATIVE FOR REGULATING THYMIC STROMAL LYMPHOID PROTEIN-MEDIATED SIGNALING AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ALLERGY AND ASTHMA DISEASES COMPRISING SAME KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) 2018-05-31 — — US disclosed
EP-3272765-A1 PEPTIDE DERIVATIVE FOR REGULATING THYMIC STROMAL LYMPHOID PROTEIN-MEDIATED SIGNALING AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ALLERGY AND ASTHMA DISEASES COMPRISING SAME Korea University Research and Business Foundation, Sejong Campus (KR) 2018-01-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148474-A1 PEPTIDE DERIVATIVE FOR REGULATING THYMIC STROMAL LYMPHOID PROTEIN-MEDIATED SIGNALING AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ALLERGY AND ASTHMA DISEASES COMPRISING SAME TSLP, CXCL12, CCL11 KISS1R 3485/4885GHSR 2712/4885IL23R 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback